Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from BetterLife Pharma ( (TSE:BETR) ) is now available.
BetterLife Pharma has appointed Dr. Steven Sangha to its Board of Directors, bringing over 25 years of experience in investment banking, business development, and asset management. Dr. Sangha, a major shareholder, believes in the potential of BETR-001 to disrupt the treatment of depression, anxiety, PTSD, and addiction. His expertise is expected to aid BetterLife in advancing its non-hallucinogenic compounds for psychiatric and neurological disorders, potentially impacting the company’s operations and industry positioning.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing compounds to treat neuro-psychiatric and neurological disorders. Its primary products include BETR-001, a non-hallucinogenic LSD derivative, and BETR-002, based on honokiol, both in preclinical and IND-enabling studies.
YTD Price Performance: -22.67%
Average Trading Volume: 17,651
Technical Sentiment Signal: Strong Buy
Current Market Cap: $8.15M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.